ligand pharma - LGND
LGND
Close Chg Chg %
288.83 -1.85 -0.64%
Open Market
286.99
-1.85 (0.64%)
Volume: 40.10K
Last Updated:
Sep 9, 2026, 10:32 AM EDT
Company Overview: ligand pharma - LGND
LGND Key Data
| Open $288.03 | Day Range 286.65 - 291.82 |
| 52 Week Range 161.82 - 326.63 | Market Cap $5.69B |
| Shares Outstanding 19.94M | Public Float 19.45M |
| Beta 1.14 | Rev. Per Employee N/A |
| P/E Ratio 30.53 | EPS $10.01 |
| Yield 0.00% | Dividend $30.01 |
| EX-DIVIDEND DATE Nov 2, 2022 | SHORT INTEREST N/A |
| AVERAGE VOLUME 203.06K |
LGND Performance
| 1 Week | 1.13% | ||
| 1 Month | -1.47% | ||
| 3 Months | 13.03% | ||
| 1 Year | 74.26% | ||
| 5 Years | 147.75% |
LGND Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
10
Full Ratings ➔
About ligand pharma - LGND
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
LGND At a Glance
Ligand Pharmaceuticals, Inc.
555 Heritage Drive
Jupiter, Florida 33458
| Phone | 1-858-550-7500 | Revenue | 268.09M | |
| Industry | Pharmaceuticals: Major | Net Income | 124.45M | |
| Sector | Health Technology | 2025 Sales Growth | 60.403% | |
| Fiscal Year-end | 12 / 2026 | Employees | 47 | |
| View SEC Filings |
LGND Valuation
| P/E Current | 30.533 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 30.831 |
| Price to Sales Ratio | 14.312 |
| Price to Book Ratio | 3.675 |
| Price to Cash Flow Ratio | 77.74 |
| Enterprise Value to EBITDA | 43.944 |
| Enterprise Value to Sales | 13.26 |
| Total Debt to Enterprise Value | 0.127 |
LGND Efficiency
| Revenue/Employee | 5,703,978.723 |
| Income Per Employee | 2,647,936.17 |
| Receivables Turnover | 4.391 |
| Total Asset Turnover | 0.214 |
LGND Liquidity
| Current Ratio | 22.225 |
| Quick Ratio | 21.982 |
| Cash Ratio | 19.588 |
LGND Profitability
| Gross Margin | 82.373 |
| Operating Margin | 17.606 |
| Pretax Margin | 59.294 |
| Net Margin | 46.423 |
| Return on Assets | 9.947 |
| Return on Equity | 13.471 |
| Return on Total Capital | 8.474 |
| Return on Invested Capital | 10.804 |
LGND Capital Structure
| Total Debt to Total Equity | 44.385 |
| Total Debt to Total Capital | 30.741 |
| Total Debt to Total Assets | 28.93 |
| Long-Term Debt to Equity | 44.277 |
| Long-Term Debt to Total Capital | 30.666 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Ligand Pharma - LGND
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 196.25M | 131.31M | 167.13M | 268.09M | |
Sales Growth
| -29.19% | -33.09% | +27.28% | +60.40% | |
Cost of Goods Sold (COGS) incl D&A
| 77.10M | 43.29M | 46.33M | 47.26M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 43.39M | 37.41M | 37.38M | 33.70M | |
Depreciation
| 9.32M | 4.63M | 4.43M | 991.00K | |
Amortization of Intangibles
| 34.07M | 32.78M | 32.96M | 32.71M | |
COGS Growth
| -29.41% | -43.85% | +7.03% | +1.99% | |
Gross Income
| 119.14M | 88.03M | 120.80M | 220.83M | |
Gross Income Growth
| -29.04% | -26.12% | +37.23% | +82.81% | |
Gross Profit Margin
| +60.71% | +67.03% | +72.28% | +82.37% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 106.31M | 78.20M | 102.98M | 174.83M | |
Research & Development
| 36.25M | 25.41M | 21.43M | 81.18M | |
Other SG&A
| 70.06M | 52.79M | 81.55M | 93.65M | |
SGA Growth
| -16.04% | -26.44% | +31.68% | +69.77% | |
Other Operating Expense
| - | - | (5.20M) | (1.20M) | - |
Unusual Expense
| - | 5.61M | 92.31M | (84.47M) | |
EBIT after Unusual Expense
| 7.23M | 9.82M | (69.29M) | 131.67M | |
Non Operating Income/Expense
| 30.58M | 54.49M | 74.85M | 32.00M | |
Non-Operating Interest Income
| 2.05M | 7.71M | 8.05M | 13.66M | |
Equity in Earnings of Affiliates
| - | - | - | (7.02M) | - |
Interest Expense
| 1.80M | 656.00K | 3.04M | 4.71M | |
Interest Expense Growth
| -90.83% | -63.54% | +362.96% | +55.25% | |
Gross Interest Expense
| 1.80M | 656.00K | 3.04M | 4.71M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 36.01M | 63.66M | 2.52M | 158.96M | |
Pretax Income Growth
| -23.86% | +76.78% | -96.04% | +6,212.95% | |
Pretax Margin
| +18.35% | +48.48% | +1.51% | +59.29% | |
Income Tax
| 41.23M | 9.84M | 6.55M | 34.51M | |
Income Tax - Current - Domestic
| 10.29M | (968.00K) | 19.00M | 9.01M | |
Income Tax - Current - Foreign
| 452.00K | 780.00K | 3.35M | 3.61M | |
Income Tax - Deferred - Domestic
| 30.49M | 10.03M | (17.69M) | 28.11M | |
Income Tax - Deferred - Foreign
| - | - | 1.89M | (6.22M) | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | (7.02M) | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (5.22M) | 53.82M | (4.03M) | 124.45M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (5.22M) | 53.82M | (4.03M) | 124.45M | |
Net Income Growth
| -109.13% | +1,131.21% | -107.49% | +3,186.63% | |
Net Margin Growth
| -2.66% | +40.98% | -2.41% | +46.42% | |
Extraordinaries & Discontinued Operations
| - | - | (28.14M) | (1.67M) | - |
Discontinued Operations
| - | - | (28.14M) | (1.67M) | - |
Net Income After Extraordinaries
| (33.36M) | 52.15M | (4.03M) | 124.45M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (33.36M) | 52.15M | (4.03M) | 124.45M | |
EPS (Basic)
| -1.9778 | 3.015 | -0.2204 | 6.4357 | |
EPS (Basic) Growth
| -157.56% | +252.44% | -107.31% | +3,020.01% | |
Basic Shares Outstanding
| 16.87M | 17.30M | 18.29M | 19.34M | |
EPS (Diluted)
| -1.9778 | 2.9371 | -0.2204 | 6.1325 | |
EPS (Diluted) Growth
| -159.70% | +248.50% | -107.50% | +2,882.44% | |
Diluted Shares Outstanding
| 16.87M | 17.76M | 18.29M | 20.29M | |
EBITDA
| 56.23M | 47.23M | 60.41M | 80.90M | |
EBITDA Growth
| -39.04% | -16.00% | +27.89% | +33.92% | |
EBITDA Margin
| +28.65% | +35.97% | +36.14% | +30.18% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 342.818 | |
| Number of Ratings | 10 | Current Quarters Estimate | 2.303 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | 9.315 | |
| Last Quarter’s Earnings | 2.37 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 8.13 | Next Fiscal Year Estimate | 12.113 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 9 | 9 | 8 |
| Mean Estimate | 2.30 | 3.01 | 9.32 | 12.11 |
| High Estimates | 2.49 | 3.26 | 9.50 | 13.33 |
| Low Estimate | 1.93 | 2.79 | 9.09 | 11.34 |
| Coefficient of Variance | 8.30 | 4.33 | 1.32 | 5.36 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 10 | 10 | 8 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Ligand Pharma - LGND
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Ligand Pharma - LGND
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Jason Haas Director | 10,442 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $51.56 per share | 538,389.52 |
| Jun 17, 2026 | Jason Haas Director | 11,442 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $51.56 per share | 589,949.52 |
| Jun 17, 2026 | Jason Haas Director | 8,442 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $255.01 per share | 2,152,794.42 |
| Jun 17, 2026 | Jason Haas Director | 4,981 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $256.08 per share | 1,275,534.48 |
| Jun 17, 2026 | Jason Haas Director | 7,138 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 17, 2026 | Jason Haas Director | 6,138 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 26, 2026 | Stephen L. Sabba Director | 32,793 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $207.87 per share | 6,816,680.91 |
| Mar 6, 2026 | Stephen L. Sabba Director | 33,793 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $201.5 per share | 6,809,289.50 |
| Mar 6, 2026 | Stephen L. Sabba Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 8, 2026 | John W. Kozarich Director | 44,100 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $186.59 per share | 8,228,619.00 |
| Jan 8, 2026 | John W. Kozarich Director | 44,009 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $187.95 per share | 8,271,491.55 |
| Jan 8, 2026 | John W. Kozarich Director | 43,907 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $188.96 per share | 8,296,666.72 |
| Jan 8, 2026 | John W. Kozarich Director | 43,700 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $190.27 per share | 8,314,799.00 |
| Jan 8, 2026 | John W. Kozarich Director | 43,654 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $192.4 per share | 8,399,029.60 |
| Jan 8, 2026 | Octavio Espinoza Chief Financial Officer | 28,575 | Other acquisition or disposition Non-derivative transaction at $95.68 per share | 2,734,056.00 |